Hippocampal Dosimetry Predicts Neurocognitive Function Impairment After Fractionated Stereotactic Radiotherapy for Benign or Low-Grade Adult Brain Tumors
- 1. Department of Human Oncology, University of Wisconsin, Madison, WI (United States)
- 2. Department of Neurology, University of Wisconsin, Madison, WI (United States)
- 3. Department of Radiation Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL (United States)
- 4. Department of Biomedical Engineering, University of Wisconsin, Madison, WI (United States)
- 5. Department of Medical Physics, University of Wisconsin, Madison, WI (United States)
Description
Purpose: To prospectively evaluate the association between hippocampal dose and long-term neurocognitive function (NCF) impairment for benign or low-grade adult brain tumors treated with fractionated stereotactic radiotherapy (FSRT). Methods and Materials: Adult patients with benign or low-grade adult brain tumors were treated with FSRT per institutional practice. No attempt was made to spare the hippocampus. NCF testing was conducted at baseline and 18 months follow-up, on a prospective clinical trial. Regression-based standardized z scores were calculated by using similar healthy control individuals evaluated at the same test–retest interval. NCF impairment was defined as a z score ≤−1.5. After delineation of the bilateral hippocampi according to the Radiation Therapy Oncology Group contouring atlas, dose–volume histograms were generated for the left and right hippocampi and for the composite pair. Biologically equivalent doses in 2-Gy fractions (EQD2) assuming an α/β ratio of 2 Gy were computed. Fisher's exact test and binary logistic regression were used for univariate and multivariate analyses, respectively. Dose–response data were fit to a nonlinear model. Results: Of 29 patients enrolled in this trial, 18 completed both baseline and 18-month NCF testing. An EQD2 to 40% of the bilateral hippocampi >7.3 Gy was associated with impairment in Wechsler Memory Scale-III Word List (WMS-WL) delayed recall (odds ratio [OR] 19.3; p = 0.043). The association between WMS-WL delayed recall and EQD2 to 100% of the bilateral hippocampi >0.0 Gy trended to significance (OR 14.8; p = 0.068). Conclusion: EQD2 to 40% of the bilateral hippocampi greater than 7.3 Gy is associated with long-term impairment in list-learning delayed recall after FSRT for benign or low-grade adult brain tumors. Given that modern intensity-modulated radiotherapy techniques can reduce the dose to the bilateral hippocampi below this dosimetric threshold, patients should be enrolled in ongoing prospective trials of hippocampal sparing during cranial irradiation to confirm these preliminary results.
Availability note (English)
Available from http://dx.doi.org/10.1016/j.ijrobp.2012.11.031Additional details
Identifiers
- DOI
- 10.1016/j.ijrobp.2012.11.031;
- PII
- S0360-3016(12)03829-1;
Publishing Information
- Journal Title
- International Journal of Radiation Oncology, Biology and Physics
- Journal Volume
- 85
- Journal Issue
- 2
- Journal Page Range
- p. 348-354
- ISSN
- 0360-3016
- CODEN
- IOBPD3
INIS
- Country of Publication
- United States
- Country of Input or Organization
- International Atomic Energy Agency (IAEA)
- INIS RN
- 44104428
- Subject category
- S62: RADIOLOGY AND NUCLEAR MEDICINE;
- Descriptors DEI
- ADULTS; CLINICAL TRIALS; DOSE EQUIVALENTS; DOSIMETRY; HIPPOCAMPUS; IRRADIATION; MULTIVARIATE ANALYSIS; NEOPLASMS; PATIENTS; RADIATION DOSES; RADIOTHERAPY
- Descriptors DEC
- AGE GROUPS; BODY; BRAIN; CENTRAL NERVOUS SYSTEM; DISEASES; DOSES; MATHEMATICS; MEDICINE; NERVOUS SYSTEM; NUCLEAR MEDICINE; ORGANS; RADIOLOGY; STATISTICS; TESTING; THERAPY
Optional Information
- Copyright
- Copyright (c) 2013 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.